Spruce Biosciences Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
25
- Stock Symbol
-
SPRB
- Share Price
-
$0.07
- (As of Monday Closing)
Spruce Biosciences General Information
Description
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The pipeline products of the company include Tralesinidase Alfa (TA-ERT), and Tildacerfont/ Cortibon, a Companion Diagnostic, developed in partnership with HMNC Brain Health.
Contact Information
Website
sprucebio.comCorporate Office
- 611 Gateway Boulevard
- Suite 740
- South San Francisco, CA 94080
- United States
Corporate Office
- 611 Gateway Boulevard
- Suite 740
- South San Francisco, CA 94080
- United States
Spruce Biosciences Stock Performance
As of 07-Jul-2025, Spruce Biosciences’s stock price is $0.07. Its current market cap is $2.96M with 42.2M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.07 | $0.07 | $0.06 - $0.61 | $2.96M | 42.2M | 1.43M | -$1.32 |
Spruce Biosciences Financials Summary
As of 31-Mar-2025, Spruce Biosciences has a trailing 12-month revenue of $2.91M.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | (44,843) | (39,478) | 16,312 | (58,256) |
| Revenue | 2,909 | 4,911 | 10,089 | 0 |
| EBITDA | (57,973) | (56,105) | (51,923) | (47,209) |
| Net Income | (55,452) | (53,036) | (47,919) | (46,180) |
| Total Assets | 31,649 | 45,209 | 103,946 | 85,648 |
| Total Debt | 2,295 | 2,765 | 4,609 | 6,315 |
Spruce Biosciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Spruce Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Spruce Biosciences Comparisons
Industry
Financing
Details
Spruce Biosciences Competitors (3)
One of Spruce Biosciences’s 3 competitors is Crinetics Pharmaceuticals, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Crinetics Pharmaceuticals | Formerly VC-backed | San Diego, CA | ||||
| Gelesis Holdings | Formerly VC-backed | Boston, MA | ||||
| Ascendis Pharma | Formerly VC-backed | Hellerup, Denmark |
Spruce Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Spruce Biosciences Patents
Spruce Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3235958-A1 | Crystalline composition of tildacerfont and methods of use and preparation thereof | Pending | 19-Nov-2021 | ||
| EP-4402142-A1 | Crystalline composition of tildacerfont and methods of use and preparation thereof | Pending | 19-Nov-2021 | ||
| US-11708372-B2 | Crystalline composition of tildacerfont and methods of use and preparation thereof | Active | 19-Nov-2021 | ||
| US-20230159533-A1 | Crystalline composition of tildacerfont and methods of use and preparation thereof | Active | 19-Nov-2021 | ||
| US-20240043432-A1 | Crystalline composition of tildacerfont and methods of use and preparation thereof | Inactive | 19-Nov-2021 | C07D487/04 |
Spruce Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Spruce Biosciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Spruce Biosciences ESG
Risk Overview
Risk Rating
Updated August, 30, 2022
27.35 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,912
Rank
Percentile
Pharmaceuticals
Industry
of 965
Rank
Percentile
Biotechnology
Subindustry
of 443
Rank
Percentile
Spruce Biosciences FAQs
-
When was Spruce Biosciences founded?
Spruce Biosciences was founded in 2016.
-
Where is Spruce Biosciences headquartered?
Spruce Biosciences is headquartered in South San Francisco, CA.
-
What is the size of Spruce Biosciences?
Spruce Biosciences has 25 total employees.
-
What industry is Spruce Biosciences in?
Spruce Biosciences’s primary industry is Biotechnology.
-
Is Spruce Biosciences a private or public company?
Spruce Biosciences is a Public company.
-
What is Spruce Biosciences’s stock symbol?
The ticker symbol for Spruce Biosciences is SPRB.
-
What is the current stock price of Spruce Biosciences?
As of 07-Jul-2025 the stock price of Spruce Biosciences is $0.07.
-
What is the current market cap of Spruce Biosciences?
The current market capitalization of Spruce Biosciences is $2.96M.
-
What is Spruce Biosciences’s current revenue?
The trailing twelve month revenue for Spruce Biosciences is $2.91M.
-
Who are Spruce Biosciences’s competitors?
Crinetics Pharmaceuticals, Gelesis Holdings, and Ascendis Pharma are competitors of Spruce Biosciences.
-
What is Spruce Biosciences’s annual earnings per share (EPS)?
Spruce Biosciences’s EPS for 12 months was -$1.32.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
